Quintiles Transnational Holdings Inc (Q) : Arvest Bank Trust Division reduced its stake in Quintiles Transnational Holdings Inc by 0.49% during the most recent quarter end. The investment management company now holds a total of 242,201 shares of Quintiles Transnational Holdings Inc which is valued at $19,245,291 after selling 1,182 shares in Quintiles Transnational Holdings Inc , the firm said in a disclosure report filed with the SEC on Oct 7, 2016.Quintiles Transnational Holdings Inc makes up approximately 1.62% of Arvest Bank Trust Division’s portfolio.
Other Hedge Funds, Including , Advisory Services Network reduced its stake in Q by selling 687 shares or 63.14% in the most recent quarter. The Hedge Fund company now holds 401 shares of Q which is valued at $31,863. Quintiles Transnational Holdings Inc makes up approx 0.01% of Advisory Services Network’s portfolio.Bnp Paribas Arbitrage Sa reduced its stake in Q by selling 16,031 shares or 37.14% in the most recent quarter. The Hedge Fund company now holds 27,129 shares of Q which is valued at $2,184,970. Quintiles Transnational Holdings Inc makes up approx 0.01% of Bnp Paribas Arbitrage Sa’s portfolio.Chevy Chase Trust Holdings reduced its stake in Q by selling 112,716 shares or 78.13% in the most recent quarter. The Hedge Fund company now holds 31,552 shares of Q which is valued at $2,541,198. Quintiles Transnational Holdings Inc makes up approx 0.01% of Chevy Chase Trust Holdings’s portfolio.Independent Portfolio Consultants reduced its stake in Q by selling 10 shares or 6.45% in the most recent quarter. The Hedge Fund company now holds 145 shares of Q which is valued at $11,678.
Quintiles Transnational Holdings Inc opened for trading at $79.07 and hit $79.69 on the upside on Friday, eventually ending the session at $79.46, with a gain of 0.24% or 0.19 points. The heightened volatility saw the trading volume jump to 13,48,221 shares. Company has a market cap of $9,414 M.
On the company’s financial health, Quintiles Transnational Holdings Inc reported $0.93 EPS for the quarter, beating the analyst consensus estimate by $ 0.03 according to the earnings call on Jul 27, 2016. Analyst had a consensus of $0.90. The company had revenue of $1167.10 million for the quarter, compared to analysts expectations of $1150.61 million. The company’s revenue was up 8.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.78 EPS.
Many Wall Street Analysts have commented on Quintiles Transnational Holdings Inc. Goldman Initiated Quintiles Transnational Holdings Inc on Oct 5, 2016 to “Buy”, Price Target of the shares are set at $94.Company shares were Reiterated by UBS on Oct 5, 2016 to “Buy”, Firm has raised the Price Target to $ 90 from a previous price target of $78 .Quintiles Transnational Holdings Inc was Upgraded by Avondale to ” Mkt Outperform” on Jul 12, 2016.
Quintiles Transnational Holdings Inc. is a biopharmaceutical services company. The Company is a provider of biopharmaceutical development services and commercial outsourcing services. The Company is engaged in the development and commercialization of pharmaceutical therapies. It also offers therapeutic scientific and analytical services to its biopharmaceutical and other healthcare customers. The Company offers its services through two segments: Product Development and Integrated Healthcare Services. Its product development segment is a contract research organization (CRO) and is focused on Phase II-IV clinical trials and associated laboratory and analytical activities. Its Integrated Healthcare Services segment provides services including commercial services such as contract pharmaceutical sales forces and healthcare business services such as phase research market access and consulting and health information analytics and technology consulting.